Publication Name	World Journal of Diabetes
Manuscript ID	46593
Country	Ukraine

Received	2019-02-17 14:46
Peer-Review Started	2019-02-18 03:23
To Make the First Decision	2019-02-20 00:31
Return for Revision	2019-02-20 01:30
Revised	2019-03-10 13:02
Second Decision	2019-03-11 10:43
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-03-11 18:04
Articles in Press	2019-03-11 18:04
Publication Fee Transferred
Edit the Manuscript by Language Editor	2019-03-15 00:29
Typeset the Manuscript	2019-03-15 00:44
Publish the Manuscript Online	2019-03-15 07:18

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	Crosstalk between gut microbiota and antidiabetic drug action
Manuscript Source	Invited Manuscript
All Author List	Yevheniia Kyriachenko, Tetyana Falalyeyeva, Oleksandr Korotkyi, Nataliia Molochek and Nazarii Kobyliak
Funding Agency and Grant Number
Corresponding Author	Nazarii Kobyliak, PhD, Assistant Professor, Department of Endocrinology, Bogomolets National Medical University, Bogomolets National Medical University, T. Shevchenko boulevard, 13, Kyiv, 01601, Ukraine. nazariikobyliak@gmail.com., Kyiv 01601, Ukraine. nazariikobyliak@gmail.com
Key Words	Type 2 diabetes; Gut microbiota; Metformin; α-glucosidase inhibitors; Glucagon-like peptide-1 agonists; Peroxisome proliferator-activated receptors γ agonists; Dipeptidyl peptidase-4 inhibitors; Sodium/glucose cotransporter inhibitors
Core Tip	Gut microbiota was found to have an influence on host metabolism, food consumption, satiety, glucose homoeostasis and weight gain. Altered intestinal microbiota composition has been noticed in cardiovascular diseases, colon cancer, rheumatoid arthritis, type 2 diabetes and obesity. Therefore, the main effect of anti-diabetic drugs is on the microbiome composition, basically increasing the short-chain fatty acids-producing bacteria, responsible for losing weight and suppressing the inflammation.
Publish Date	2019-03-15 07:18
Citation	Kyriachenko Y, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and anti-diabetic drug action. World J Diabetes 2019; 10(3): 154-168
URL	https://www.wjgnet.com/1948-9358/full/v10/i3/154.htm
DOI	https://dx.doi.org/10.4239/wjd.v10.i3.154

Full Article (PDF)	WJD-10-154.pdf
Full Article (Word)	WJD-10-154.docx
Manuscript File	FP6796-46593-Review.docx
Answering Reviewers	46593-Answering reviewers.pdf
Audio Core Tip	46593-Audio core tip.wma
Conflict-of-Interest Disclosure Form	46593-Conflict-of-interest statement.pdf
Copyright License Agreement	46593-Copyright license agreement.pdf
Peer-review Report	46593-Peer-review(s).pdf
Scientific Misconduct Check	46593-Scientific misconduct check.pdf
Scientific Editor Work List	46593-Scientific editor work list.pdf